Search

for
Search:

Research

5 / 1000+ results

An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial

research An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial

6 citations , October 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that early pharmacological treatment of COVID-19 in females, including those with hyperandrogenic conditions, significantly improved clinical outcomes, with spironolactone users experiencing milder symptoms and faster recovery.

Hydroxychloroquine, Nitazoxanide, and Ivermectin Have Similar Effects in Early COVID-19: A Head-to-Head Comparison of the Pre-AndroCoV Trial

research Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.

4 citations , October 2020 in “Research Square (Research Square)”

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.